High clinical impact of rapid susceptibility testing on CHROMID ESBL® medium directly from swabs | Zendy

Álvaro Romo-Ibáñez | Zendy; Elisabeth Calatrava-Hernández | Zendy; Blanca Gutiérrez-Soto | Zendy; Mercedes Pérez-Ruiz | Zendy; José María NavarroMarí | Zendy; José Gutiérrez Fernández | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

High clinical impact of rapid susceptibility testing on CHROMID ESBL® medium directly from swabs

Author(s) -

Álvaro Romo-Ibáñez,

Elisabeth Calatrava-Hernández,

Blanca Gutiérrez-Soto,

Mercedes Pérez-Ruiz,

José María NavarroMarí,

José Gutiérrez Fernández

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.02.158

Subject(s) - imipenem , microbiology and biotechnology , enterococcus faecium , vancomycin , cefoxitin , stenotrophomonas maltophilia , acinetobacter baumannii , enterococcus faecalis , antibiotics , biology , carbapenem , medicine , antibiotic resistance , bacteria , pseudomonas aeruginosa , staphylococcus aureus , genetics

CHROMID ESBL medium permitted the differential growth of Gram-negative bacteria, many with ESBL and carbapenemases. ESBL enterobacteria were susceptible to imipenem, carbapenemase-producing microorganisms grew around the imipenem disk, and vancoR was isolated on the medium. Results of the prospective study demonstrate the potential clinical relevance of this medium. was more frequently detected with pharyngeal swabs and ESBL , A. and with rectal swabs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research